Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter 2022 Financial Results on March 7, 2023
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) will release its fourth-quarter financial results for the period ending December 31, 2022, on March 7, 2023.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Participants may access the conference call via webcast on the Investor page of Marinus’ website at ir.marinuspharma.com/events-and-presentations. An archived version of the call will be available approximately two hours after the completion of the event on the website.
About
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY® (ganaxolone) oral suspension CV, has been approved by the
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005156/en/
Company Contact
Senior Vice President, Corporate Affairs & Investor Relations
sdamouni@marinuspharma.com
Source: